Follow us on social media
Support teaching, research, and patient care.
Newly Diagnosed
ACNS1833: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1) Diagnosis: Low-Grade Glioma (LGG)
DAY101: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy Diagnosis: Low-Grade Glioma (LGG) with RAF Alteration
Recurrent/Refractory/Progressive
There are currently no open trials
GD2 CAR-T: Phase 1 Clinical Trial of Autologous GD2 Chimeric Antigen Receptor (CAR) T cells (GD2CART) for Diffuse Intrinsic Pontine Gliomas (DIPG) and Spinal Diffuse Midline Glioma (DMG)
Diagnosis: Diffuse Intrinsic Pontine Glioma (DIPG) and Spinal Cord Diffuse Midline Glioma (DMG) that is H3K27 mutated
There are currently no open trials.
Eli Lilly: A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
Diagnosis: High-Grade Glioma (HGG)
ACNS1821: A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
Diagnosis: High-Grade Glioma (HGG) / ONLY HGG Stratum Open
There are currently no trials for Newly Diagnosed Ependymomas.
SJiMB21: Phase 2 Study of Molecular and Clinical Risk-Directed Therapy for Infants and Young Children with Newly Diagnosed Medulloblastoma Diagnosis: Medulloblastoma
BCC016: DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
Diagnosis: Relapsed Medulloblastoma
No current Atypical Teratoid Rhabdoid Tumor trials
No current Neurofibromatosis-1 (NF1) recurrent/refractory/progressive trials
Other - nontreatment
NF1-OPG Natural History Study: Developing Evidence-Based Criteria for Initiating Treatment for Neurofibromatosis Type 1 Associated Optic Pathway Glioma/CTF 004: The Collection of Blood Samples from Patients with NF1 for Research Purposes Diagnosis: Optic pathway glioma
NF1 Patient Registry Diagnosis: NF
Other & Molecular Based Therapies
ACNS2321: A Phase II Trial Evaluating Chemotherapy followed by Response-Based Reduced Radiation Therapy for Patients with Central Nervous System Germinomas Diagnosis: Newly diagnosed germinoma
ACNS2021: A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor Diagnosis: Newly diagnosed with localized primary CNS NGGCT of the suprasellar and/or pineal region
G042286: A Phase I/II, Open-Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available Diagnosis: CNS or solid tumors harboring ALK gene fusions
APEC14B1: The Project: Everychild Protocol: A Registry, Eligibility, Screening, Biology, and Outcome Study Diagnosis: Registry or eligibility arm
Further Information and Summaries for Health Care Professionals
The Children's Oncology Group
To find out the current status of any study please contact us at:
Merkel@stanford.edu
jmaala@stanford.edu